897 |
The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses |
David Joel Cohen |
Jul. 22. 09 |
896 |
Medical Statistics 101: Basic Comparative Statistics, Parametric and Non Parametric P Values and Confidence Intervals, Trial Size |
Donald E. Cutlip |
Jul. 22. 09 |
895 |
Regulatory Perspectives Of Clinical Trials: What Core Elements does FDA Look for? |
Heather Agler |
Jul. 22. 09 |
894 |
Responsibilities of Investigators in Clinical Trials: From Consent to Safety Reporting |
Young-Hak Kim |
Jul. 22. 09 |
893 |
Quality Control of Clinical Trials: Blinding, Clinical Event Committees, Core Labs, and Data Standards |
Roxana Mehran |
Jul. 22. 09 |
892 |
Utility and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials |
Helen Parise |
Jul. 22. 09 |
891 |
Randomized Trials vs. Observational Registries: Strengths and Weaknesses |
David Joel Cohen |
Jul. 22. 09 |
890 |
Non-Invasive Imaging Is More Clinically Relevant ! |
James K. Min |
Jul. 22. 09 |
889 |
Percutaneous Therapy of Structural Heart Disease Using Imaging Modality |
Ted Feldman |
Jul. 21. 09 |
888 |
Vulnerable Plaque Trials Using Surrogate Imaging Marker |
Patrick W. Serruys |
Jul. 21. 09 |